Business Wire
Proprietary Feature Demonstrates Advanced Accuracy in Mitigating Copay Maximizers
Paysign, Inc., a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced its annual performance analysis of pharmaceutical copay programs leveraging their patient affordability solutions. Paysign’s dynamic business rules feature, which the company introduced in 2022 to mitigate the harmful financial impact of copay maximizers on both patients and pharmaceutical program sponsors, saved their clients more than $100 million in 2024 alone. Due to its ability to identify impacted claims on the first fill with 97% accuracy, this technology is an industry first and unique in the marketplace.
Read More:Â AI Can Save E-commerce Vendors from Cash Flow Squeeze
Annual product data found the company’s innovative patient affordability solutions achieved these noteworthy successes in 2024:
- Saved over $100 million for pharmaceutical program sponsors by shielding funds from being diverted
- Supported 66+ retail and specialty pharmaceutical programs in diverse therapeutic classes
- Assisted more than 500,000 unique patients – a figure that more than doubled compared to 2023
- Powered programs that contributed more than $600 million toward prescription fulfillment expenses
“2024 was a pivotal year for our patient affordability business,” said Matt Turner, President of Patient Affordability at Paysign. “An increasing number of the world’s largest pharmaceutical companies trusted our technologies to help remove financial hurdles their patients face when starting or continuing therapy. Our team’s dedication and adaptability in addressing copay maximizer risks has proven invaluable, and we are proud to lessen the financial burden on patients.”
As these 2024 results demonstrate, Paysign is steadily broadening its presence across the healthcare ecosystem. The accomplishments in patient and client savings highlight the advanced efficacy of Paysign’s solutions.
“Achieving these milestones is a testament to the true spirit of innovation we put into the patient affordability suite of solutions,” said Mark Newcomer, Chief Executive Officer of Paysign. “I’m thrilled to see Paysign continue its expansion in healthcare and life sciences, and we remain committed to enhancing our capabilities in this space.”
Paysign’s innovative patient affordability platform offers tools that can be configured to the specific needs of each copay assistance program and pharmaceutical manufacturers’ brand strategies. Dynamic business rules – the platform’s standout capability – enables real-time modifications to program criteria to reduce the impact of copay maximizers, ensuring seamless benefit experiences for patients and providers.
Read More:Â Global Fintech Series Interview with Jeff Marsden, Chief Product Officer at PureFacts
[To share your insights with us, please write to psen@itechseries.com ]
